NO991701L - HIV and cancer treatment - Google Patents
HIV and cancer treatmentInfo
- Publication number
- NO991701L NO991701L NO991701A NO991701A NO991701L NO 991701 L NO991701 L NO 991701L NO 991701 A NO991701 A NO 991701A NO 991701 A NO991701 A NO 991701A NO 991701 L NO991701 L NO 991701L
- Authority
- NO
- Norway
- Prior art keywords
- hiv
- cancer
- herbicide
- fungicide
- virus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
En metode for å behandle HIV og andre virusinfeksjoner ved administrering av et herbicid eller fungicid eller derivat derav til et dyr eller menneske. Fungicidene eller herbi- cidene kan anvendes sammen med andre behandlinger, f.eks. med AZT- eller protease-inhibitorer for behandling av HIV. Tiabendazol og klorpropam er f.eks. blitt vist til raskt å redusere nivået av virusproduksjon fra cellepopulasjoner som er kronisk infisert med HIV-l og den antivirale effekt opprettholdes med fortsatt forbindelseseksponering. Denne reduksjon av virusproduksjon forekommer ved konsentrasjoner som er ikke-toksiske for vertscellen og som ikke har noen effekt på syntesen av cellulært DNA, RNA og protein. Videre ble kronisk infiserte celler behandlet i forlengede tidsperioder med tiabendazol og klorpropam ikke superinfisert med HIV. En metode for å inhibere vekst av tumorer og cancere i pattedyr som omfatter administrering av et herbicid- eller fungicidderivat er også angitt heri. Fungicidene eller herbicidene kan anvendes sammen med andre behandlinger, f.eks. taxol for behandlingen av bryst-cancer. Forsterkere kan også være inkludert i det herbicide eller fungicide pre- parat. Metoden er særlig effektiv når canceren eller viruset er en animalsk celle som er genetisk modifisert med plante- eller sopp-genetisk material. Et kjemoterapeutisk middel kan også først administreres for å signifikant redusere størrel- sen av canceren og deretter anvendes behandlingen med herbicidet eller_fungicidet. pisse_metpder er særlig effekti- ve når canceren eller viruset er en mutert celle som omfatter plante- eller sopp-genetisk"material.A method of treating HIV and other viral infections by administering a herbicide or fungicide or derivative thereof to an animal or human. The fungicides or herbicides can be used with other treatments, e.g. with AZT or protease inhibitors for the treatment of HIV. Tiabendazole and chloropropam are e.g. has been shown to rapidly reduce the level of virus production from cell populations chronically infected with HIV-1 and the antiviral effect is maintained with continued compound exposure. This reduction in virus production occurs at concentrations that are nontoxic to the host cell and which have no effect on the synthesis of cellular DNA, RNA and protein. Furthermore, chronically infected cells were treated for extended periods of time with thiabendazole and chloropropam not superinfected with HIV. A method for inhibiting the growth of tumors and cancers in mammals comprising administering a herbicide or fungicide derivative is also disclosed herein. The fungicides or herbicides can be used with other treatments, e.g. taxol for the treatment of breast cancer. Amplifiers may also be included in the herbicidal or fungicidal preparation. The method is particularly effective when the cancer or virus is an animal cell genetically modified with plant or fungal genetic material. A chemotherapeutic agent may also be administered first to significantly reduce the size of the cancer and then the treatment with the herbicide or fungicide is used. piss_metpder is particularly effective when the cancer or virus is a mutated cell comprising plant or fungal genetic material.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4672697P | 1997-05-16 | 1997-05-16 | |
| PCT/US1997/021564 WO1998051303A1 (en) | 1997-05-16 | 1997-11-26 | Hiv and cancer treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO991701D0 NO991701D0 (en) | 1999-04-09 |
| NO991701L true NO991701L (en) | 2000-01-17 |
Family
ID=21945046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO991701A NO991701L (en) | 1997-05-16 | 1999-04-09 | HIV and cancer treatment |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0954309A1 (en) |
| JP (1) | JP2000510156A (en) |
| KR (1) | KR20000049064A (en) |
| CN (1) | CN1254281A (en) |
| AR (1) | AR009968A1 (en) |
| AU (1) | AU7402998A (en) |
| BR (1) | BR9712981A (en) |
| CA (1) | CA2268848A1 (en) |
| CO (1) | CO5070657A1 (en) |
| CZ (1) | CZ124999A3 (en) |
| HU (1) | HUP9904092A3 (en) |
| IL (1) | IL129351A0 (en) |
| NO (1) | NO991701L (en) |
| PE (1) | PE11499A1 (en) |
| PL (1) | PL335160A1 (en) |
| SK (1) | SK46999A3 (en) |
| TR (1) | TR199901530T2 (en) |
| WO (1) | WO1998051303A1 (en) |
| ZA (1) | ZA979095B (en) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6479526B1 (en) | 1995-04-12 | 2002-11-12 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of viruses and cancers |
| US6262093B1 (en) | 1995-04-12 | 2001-07-17 | The Proctor & Gamble Company | Methods of treating cancer with benzimidazoles |
| US6177460B1 (en) | 1995-04-12 | 2001-01-23 | The Procter & Gamble Company | Method of treatment for cancer or viral infections |
| US5770616A (en) | 1995-06-07 | 1998-06-23 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of cancers |
| US6265427B1 (en) | 1995-06-07 | 2001-07-24 | The Proctor & Gamble Company | Pharmaceutical composition for the method of treating leukemia |
| US6686391B2 (en) | 1995-08-04 | 2004-02-03 | University Of Arizona Foundation | N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions |
| US5900429A (en) | 1997-01-28 | 1999-05-04 | The Procter & Gamble Company | Method for inhibiting the growth of cancers |
| US6506783B1 (en) | 1997-05-16 | 2003-01-14 | The Procter & Gamble Company | Cancer treatments and pharmaceutical compositions therefor |
| US6245789B1 (en) * | 1998-05-19 | 2001-06-12 | The Procter & Gamble Company | HIV and viral treatment |
| WO2000050021A2 (en) * | 1999-02-26 | 2000-08-31 | Napro Biotherapeutics, Inc. | Treatment regimen for prostate cancer, initiated after androgen ablative therapy has started |
| AU3606700A (en) * | 1999-02-26 | 2000-09-14 | Napro Biotherapeutics, Inc. | Treatment regimen for hormone-sensitive cancers |
| US6423734B1 (en) | 1999-08-13 | 2002-07-23 | The Procter & Gamble Company | Method of preventing cancer |
| AU2001286744A1 (en) * | 2000-08-25 | 2002-03-04 | Beth Israel Deaconess Medical Center | Compounds and methods for inhibiting neuronal cell death |
| US6407105B1 (en) * | 2000-09-26 | 2002-06-18 | The Procter & Gamble Company | Compounds and methods for use thereof in the treatment of cancer or viral infections |
| US6380232B1 (en) | 2000-09-26 | 2002-04-30 | The Procter & Gamble Company | Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof |
| AU9279601A (en) * | 2000-09-26 | 2002-04-08 | Procter & Gamble | Compounds and methods for use thereof in the treatment of cancer or viral infections |
| US6608096B1 (en) | 2000-09-26 | 2003-08-19 | University Of Arizona Foundation | Compounds and methods for use thereof in the treatment of cancer or viral infections |
| US6462062B1 (en) | 2000-09-26 | 2002-10-08 | The Procter & Gamble Company | Compounds and methods for use thereof in the treatment of cancer or viral infections |
| AU2002239395A1 (en) * | 2000-11-01 | 2002-06-03 | The Procter And Gamble Company | Hiv treatment with benzimidazoles |
| JP2004115397A (en) * | 2002-09-25 | 2004-04-15 | Fuji Photo Film Co Ltd | Liposome comprising therapeutic agent for vascular disease |
| AU2005313839B2 (en) * | 2004-12-06 | 2010-03-11 | Pitney Pharmaceuticals Pty Limited | Treatment for cancer |
| CN101111248A (en) * | 2004-12-06 | 2008-01-23 | 新南部创新有限公司 | Treatment for cancer |
| US7727967B2 (en) * | 2006-02-24 | 2010-06-01 | Boise State University | Cyanooxime inhibitors of carbonyl reductase and methods of using said inhibitors in treatments involving anthracyclines |
| WO2009043093A1 (en) * | 2007-10-04 | 2009-04-09 | Newsouth Innovations Pty Limited | Hif inhibition |
| CN101643729B (en) * | 2008-08-07 | 2011-12-28 | 复旦大学 | Nucleic acid molecule NRN1SR22 and application thereof in preparation of anticancer medicaments |
| WO2015140792A1 (en) * | 2014-03-16 | 2015-09-24 | Hadasit Medical Research Services And Development Ltd. | Type iii deiodinase inhibitors and uses thereof |
| CN105418711A (en) * | 2015-11-06 | 2016-03-23 | 山东大学 | Application of alpha-L-rhamnosidase to preparing hydroxycarbamide and glycoside derivatives |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2139052C1 (en) * | 1993-03-31 | 1999-10-10 | Мерк Энд Ко., Инк. | Combination of hiv-protease inhibitor with other antiviral compounds, pharmaceutical composition based on said and method of pharmaceutical composition preparing |
| US5656615A (en) * | 1995-04-12 | 1997-08-12 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of cancers and viruses in mammals |
| SK138397A3 (en) * | 1995-04-12 | 1998-05-06 | Procter & Gamble | A pharmaceutical composition containing n-chlorophenylcarbamates and n-chlorophenylthiocarbamates for inhibiting the growth of viruses and cancer |
| US5665713A (en) * | 1995-04-12 | 1997-09-09 | Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of viruses and cancers |
| MX9800998A (en) * | 1995-08-04 | 1998-04-30 | Procter & Gamble | Use of fluconazole for inhibiting the growth of cancers. |
-
1997
- 1997-10-09 PE PE1997000894A patent/PE11499A1/en not_active Application Discontinuation
- 1997-10-10 AR ARP970104697A patent/AR009968A1/en unknown
- 1997-10-10 ZA ZA9709095A patent/ZA979095B/en unknown
- 1997-11-07 CO CO97065469A patent/CO5070657A1/en unknown
- 1997-11-26 IL IL12935197A patent/IL129351A0/en unknown
- 1997-11-26 HU HU9904092A patent/HUP9904092A3/en unknown
- 1997-11-26 SK SK469-99A patent/SK46999A3/en unknown
- 1997-11-26 PL PL97335160A patent/PL335160A1/en unknown
- 1997-11-26 JP JP10522997A patent/JP2000510156A/en active Pending
- 1997-11-26 CN CN97182189A patent/CN1254281A/en active Pending
- 1997-11-26 CA CA002268848A patent/CA2268848A1/en not_active Abandoned
- 1997-11-26 WO PCT/US1997/021564 patent/WO1998051303A1/en not_active Application Discontinuation
- 1997-11-26 EP EP97949599A patent/EP0954309A1/en not_active Withdrawn
- 1997-11-26 CZ CZ991249A patent/CZ124999A3/en unknown
- 1997-11-26 AU AU74029/98A patent/AU7402998A/en not_active Abandoned
- 1997-11-26 BR BR9712981-0A patent/BR9712981A/en unknown
- 1997-11-26 TR TR1999/01530T patent/TR199901530T2/en unknown
- 1997-11-26 KR KR1019990703137A patent/KR20000049064A/en not_active Application Discontinuation
-
1999
- 1999-04-09 NO NO991701A patent/NO991701L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO991701D0 (en) | 1999-04-09 |
| AR009968A1 (en) | 2000-05-17 |
| SK46999A3 (en) | 2000-05-16 |
| JP2000510156A (en) | 2000-08-08 |
| CA2268848A1 (en) | 1998-11-19 |
| EP0954309A1 (en) | 1999-11-10 |
| WO1998051303A1 (en) | 1998-11-19 |
| IL129351A0 (en) | 2000-02-17 |
| CN1254281A (en) | 2000-05-24 |
| HUP9904092A3 (en) | 2000-07-28 |
| TR199901530T2 (en) | 1999-10-21 |
| AU7402998A (en) | 1998-12-08 |
| CO5070657A1 (en) | 2001-08-28 |
| HUP9904092A2 (en) | 2000-04-28 |
| BR9712981A (en) | 2000-04-18 |
| KR20000049064A (en) | 2000-07-25 |
| ZA979095B (en) | 1998-05-11 |
| PE11499A1 (en) | 1999-03-01 |
| PL335160A1 (en) | 2000-04-10 |
| CZ124999A3 (en) | 1999-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO991701L (en) | HIV and cancer treatment | |
| BRPI0410040B1 (en) | combinations of active substances that exhibit nematicidal, insecticidal and fungicidal properties and are based on trifluorbutenyl compounds. | |
| BR112019023010A2 (en) | synergistic mixtures for fungal control in vegetables | |
| ATE142423T1 (en) | AQUEOUS DISPERSIONS OF SULFONYL UREA DERIVATIVES | |
| NO974696L (en) | Pharmaceutical preparation containing N-chlorophenylcarbamates and N-chlorophenylthiocarbamates for inhibition of virus and cancer growth | |
| EP3115394B1 (en) | Antiviral agent | |
| Reuvers et al. | Potential use of nitrofurans in radiotherapy | |
| Shcherbyna et al. | The research of 1, 2, 4-triazole derivatives hepatoprotective activity under tetracycline and infectious hepatitis | |
| KR20190032209A (en) | Composition For Controlling Plant Viruses and Use Thereof | |
| Hudson et al. | The efficacy of amantadine and other antiviral compounds against two salmonid viruses in vitro | |
| JP2004529091A5 (en) | ||
| US10624892B2 (en) | Agent against fungal infections | |
| JP7277476B2 (en) | Chemotherapeutic Agents Containing Combinations of Alexidine Dihydrochloride and Sodium Pentaborate Pentahydrate | |
| Keefer | Broad-Spectrum Anti-Cancer Activity of O 2-Arylated Diazeniumdiolates | |
| DK165100B (en) | PHOSPHATIDE CONTAINING, FUNGICID PREPARATION, ITS MANUFACTURING AND USE | |
| NO20025898L (en) | Methods and associated preparations for increasing the survival of aquatic animals and other animals exposed to an aquatic virus, birna virus or other RNA virus | |
| CN102972408B (en) | Bactericidal composition containing triazolone and fluopicolide | |
| SU638235A3 (en) | Herbicide composition | |
| Anaso et al. | Assessment of loss in yield due to sorghum downy mildew (Peronosclerospora sorghi) of maize in Nigerian guinea savanna | |
| SU1389702A1 (en) | Method of treatment of seeds prior to sowing | |
| EP4064840A1 (en) | Method to control septoria tritici resistant to c14-demethylase inhibitor fungicides | |
| Kuznetsova et al. | Comparative Action of Salsoline, Salsolidine, and Related Compounds on KML Tissue Culture and Animal Tumor Strains. | |
| Ghosh et al. | Field evaluation of some new insecticides against brown planthopper Nilaparvata lugens (stål) in rice | |
| Han et al. | In vitro plant regeneration for mass propagation of Epimedium koreanum Nakai | |
| Somers | The specificity of fungicides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |